BioWorld

March 23, 2009

View Archived Issues

Poniard's Pipeline Narrows to Picoplatin After Cost Cutting

Poniard Pharmaceuticals Inc. is cutting 12 percent of its staff and discontinuing in-house preclinical research operations, the latest in a recent spate of layoffs. (BioWorld Today) Read More

HHS, IOM Take First Steps on Comparative Effectiveness

Read More

'Endogenous Lithium' Found to Play Role in Schizophrenia

Read More

NewCo News: Otonomy Tackles Hearing and Balance Disorders with Delivery

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More